Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein E deficient mice

Marine Drugs

Volumn 13, Issue 4, 2015, Pages 2306-2326

  Zhao, Li Yan ^a   Li, Jie ^b   Yuan, Feng ^a   Li, Mei ^b   Zhang, Quan ^a   Huang, Yun Ying ^c   Pang, Ji Yan ^b   Zhang, Bin ^d   Sun, Fang Yun ^e   Sun, Hong Shuo ^f   Li, Qian ^a   Cao, Lu ^a   Xie, Yu ^a   Lin, Yong Cheng ^b   Liu, Jie ^a   Tan, Hong Mei ^a,b   Wang, Guan Lei ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e XIZANG MINZU UNIVERSITY   (China)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

apoE deficient mice; Atherosclerosis; Endothelium; eNOS; Xyloketals

Indexed keywords

APOLIPOPROTEIN E; AUTOANTIBODY; CD31 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NATURAL PRODUCT; NITRIC OXIDE; PROTEIN KINASE B; SIMVASTATIN; UNCLASSIFIED DRUG; XYLOKETAL B; ANTIOXIDANT; CARDIOVASCULAR AGENT; PYRAN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA SINUS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME PHOSPHORYLATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; LIPID DIET; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEFICIENCY; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN ENDOTHELIAL CELL; VASODILATATION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; CELL CULTURE; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENETICS; GERMFREE ANIMAL; KNOCKOUT MOUSE; LIPID METABOLISM, INBORN ERRORS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; PROTEIN PROCESSING; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM;

MUS;

ANIMALS; ANTIOXIDANTS; AORTA; APOLIPOPROTEINS E; CARDIOVASCULAR AGENTS; CELLS, CULTURED; DIET, HIGH-FAT; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPID METABOLISM, INBORN ERRORS; MALE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PYRANS; SPECIFIC PATHOGEN-FREE ORGANISMS; VASODILATION;

EID: 84928606470     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md13042306     Document Type: Article

References (54)

1. Endemann, D.H.; Schiffrin, E.L. Endothelial dysfunction. J. Am. Soc.Nephrol. 2004, 15, 1983-1992.
2. Viecili, P.R.; Borges, D.O.; Kirsten, K.; Malheiros, J.; Viecili, E.; Melo, R.D.; Trevisan, G.; da Silva, M.A.; Bochi, G.V.; Moresco, R.N.; et al. Effects of campomanesia xanthocarpa on inflammatory processes, oxidative stress, endothelial dysfunction and lipid biomarkers in hypercholesterolemic individuals. Atherosclerosis 2014, 234, 85-92.
3. Perticone, F.; Maio, R.; Perticone, M.; Sciacqua, A.; Shehaj, E.; Naccarato, P.; Sesti, G. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010, 122, 379-384.
4. Virdis, A.; Ghiadoni, L.; Cardinal, H.; Favilla, S.; Duranti, P.; Birindelli, R.; Magagna, A.; Bernini, G.; Salvetti, G.; Taddei, S.; et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J. Am. Coll. Cardiol. 2001, 38, 1106-1115.
5. Avogaro, A.; Albiero, M.; Menegazzo, L.; de Kreutzenberg, S.; Fadini, G.P. Endothelial dysfunction in diabetes: The role of reparatory mechanisms. Diabetes Care 2011, 34 (Suppl. S2), S285-S290.
6. Leone, A.; Balbarini, A. Exposure to passive smoking: A test to predict endothelial dysfunction and atherosclerotic lesions. Angiology 2008, 59, 220-223.
7. Jackson, D.E. The unfolding tale of pecam-1. FEBS Lett. 2003, 540, 7-14.
8. Suematsu, N.; Ojaimi, C.; Kinugawa, S.; Wang, Z.; Xu, X.; Koller, A.; Recchia, F.A.; Hintze, T.H. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation 2007, 115, 255-262.
9. Lei, J.; Vodovotz, Y.; Tzeng, E.; Billiar, T.R. Nitric oxide, a protective molecule in the cardiovascular system. Nitric Oxide 2013, 35, 175-185.
10. Forstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J. 2012, 33, 829-837, 837a-837d.
11. Michell, B.J.; Chen, Z.; Tiganis, T.; Stapleton, D.; Katsis, F.; Power, D.A.; Sim, A.T.; Kemp, B.E. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase c and the camp-dependent protein kinase. J. Biol. Chem. 2001, 276, 17625-17628.
12. Pettigrew, J.D.; Wilson, P.D. Synthesis of xyloketal a, b, c, d, and g analogues. J. Organ. Chem. 2006, 71, 1620-1625.
13. Lin, Y.; Wu, X.; Feng, S.; Jiang, G.; Luo, J.; Zhou, S.; Vrijmoed, L.L.; Jones, E.B.; Krohn, K.; Steingrover, K.; et al. Five unique compounds: Xyloketals from mangrove fungus xylaria sp. From the south China sea coast. J. Organ. Chem. 2001, 66, 6252-6256.
14. Xu, F.; Zhang, Y.; Wang, J.; Pang, J.; Huang, C.; Wu, X.; She, Z.; Vrijmoed, L.L.; Jones, E.B.; Lin, Y. Benzofuran derivatives from the mangrove endophytic fungus xylaria sp. (#2508). J. Nat. Prod. 2008, 71, 1251-1253.
15. Chen, W.L.; Qian, Y.; Meng, W.F.; Pang, J.Y.; Lin, Y.C.; Guan, Y.Y.; Chen, S.P.; Liu, J.; Pei, Z.; Wang, G.L. A novel marine compound xyloketal b protects against oxidized ldl-induced cell injury in vitro. Biochem. Pharmacol. 2009, 78, 941-950.
16. Xu, Z.; Li, Y.; Xiang, Q.; Pei, Z.; Liu, X.; Lu, B.; Chen, L.; Wang, G.; Pang, J.; Lin, Y. Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen. J. Med. Chem. 2010, 53, 4642-4653.
17. Zhao, J.; Li, L.; Ling, C.; Li, J.; Pang, J.Y.; Lin, Y.C.; Liu, J.; Huang, R.; Wang, G.L.; Pei, Z.; et al. Marine compound xyloketal b protects pc12 cells against ogd-induced cell damage. Brain Res. 2009, 1302, 240-247.
18. Li, Z.X.; Chen, J.W.; Yuan, F.; Huang, Y.Y.; Zhao, L.Y.; Li, J.; Su, H.X.; Liu, J.; Pang, J.Y.; Lin, Y.C.; et al. Xyloketal b exhibits its antioxidant activity through induction of ho-1 in vascular endothelial cells and zebrafish. Mar. Drugs 2013, 11, 504-522.
19. Lu, X.L.; Yao, X.L.; Liu, Z.; Zhang, H.; Li, W.; Li, Z.; Wang, G.L.; Pang, J.; Lin, Y.; Xu, Z.; et al. Protective effects of xyloketal b against mpp+-induced neurotoxicity in caenorhabditis elegans and pc12 cells. Brain Res. 2010, 1332, 110-119.
20. Wang, G.L.; Pang, J.Y.; Lin, Y.C.; Liu, J.; Xie, Y.; Liu, C.Z. Application of Xyloketal B in preparing antiatherosclerotic medicaments. Patent CN102018699B, 26 March 2014.
21. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A.M. Activation of nitric oxide synthase in endothelial cells by akt-dependent phosphorylation. Nature 1999, 399, 601-605.
22. Gonzalez, E.; Kou, R.; Lin, A.J.; Golan, D.E.; Michel, T. Subcellular targeting and agonist-induced site-specific phosphorylation of endothelial nitric-oxide synthase. J. Biol. Chem. 2002, 277, 39554-39560.
23. Nakashima, Y.; Plump, A.S.; Raines, E.W.; Breslow, J.L.; Ross, R. Apoe-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 1994, 14, 133-140.
24. Sparrow, C.P.; Burton, C.A.; Hernandez, M.; Mundt, S.; Hassing, H.; Patel, S.; Rosa, R.; Hermanowski-Vosatka, A.; Wang, P.R.; Zhang, D.; et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 115-121.
25. Palinski, W.; Ord, V.A.; Plump, A.S.; Breslow, J.L.; Steinberg, D.; Witztum, J.L. Apoe-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 1994, 14, 605-616.
26. Baglione, J.; Smith, J.D. Quantitative assay for mouse atherosclerosis in the aortic root. Methods Mol. Med. 2006, 129, 83-95.
27. Jaffe, E.A.; Nachman, R.L.; Becker, C.G.; Minick, C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Investig. 1973, 52, 2745-2756.
28. Meir, K.S.; Leitersdorf, E. Atherosclerosis in the apolipoprotein-e-deficient mouse: A decade of progress. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1006-1014.
29. Zadelaar, S.; Kleemann, R.; Verschuren, L.; de Vries-Van der Weij, J.; van der Hoorn, J.; Princen, H.M.; Kooistra, T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1706-1721.
30. Fazio, S.; Linton, M.F. Mouse models of hyperlipidemia and atherosclerosis. Front. Biosci. 2001, 6, D515-D525.
31. Lohmeier, T.E.; Dwyer, T.M.; Irwin, E.D.; Rossing, M.A.; Kieval, R.S. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 2007, 49, 1307-1314.
32. Lohmeier, T.E.; Iliescu, R.; Liu, B.; Henegar, J.R.; Maric-Bilkan, C.; Irwin, E.D. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012, 59, 331-338.
33. Erdos, B.; Kirichenko, N.; Whidden, M.; Basgut, B.; Woods, M.; Cudykier, I.; Tawil, R.; Scarpace, P.J.; Tumer, N. Effect of age on high-fat diet-induced hypertension. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H164-H172.
34. Cerf, M.E. High fat programming of beta cell compensation, exhaustion, death and dysfunction. Pediatr. Diabetes 2015, 16, 71-78.
35. Kanno, A.; Asahara, S.; Masuda, K.; Matsuda, T.; Kimura-Koyanagi, M.; Seino, S.; Ogawa, W.; Kido, Y. Compensatory hyperinsulinemia in high-fat diet-induced obese mice is associated with enhanced insulin translation in islets. Biochem. Biophys. Res. Commun. 2015, 458, 681-686.
36. Dake, B.L.; Oltman, C.L. Cardiovascular, metabolic, and coronary dysfunction in high-fat-fed obesity-resistant/prone rats. Obesity 2015, 23, 623-629.
37. Iliescu, R.; Tudorancea, I.; Irwin, E.D.; Lohmeier, T.E. Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension. Am. J. Physiol. Heart Circ. Physiol. 2013, 305, H1080-H1088.
38. McCully, B.H.; Brooks, V.L.; Andresen, M.C. Diet-induced obesity severely impairs myelinated aortic baroreceptor reflex responses. Am. J. Physiol. Heart Circ. Phys. 2012, 302, H2083-H2091.
39. McCully, B.H.; Hasan, W.; Streiff, C.T.; Houle, J.C.; Woodward, W.R.; Giraud, G.D.; Brooks, V.L.; Habecker, B.A. Sympathetic cardiac hyperinnervation and atrial autonomic imbalance in diet-induced obesity promote cardiac arrhythmias. Am. J. Physiol. Heart Circ. Phys. 2013, 305, H1530-H1537.
40. Zhao, D.; McCully, B.H.; Brooks, V.L. Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity. J. Pharmacol. Exp. Ther. 2012, 343, 206-213.
41. Rajman, I.; Kendall, M.; Cramb, R. The oxidation hypothesis of atherosclerosis. Lancet 1994, 344, 1363-1364.
42. Hulthe, J. Antibodies to oxidized ldl in atherosclerosis development - Clinical and animal studies. Clin. Chim. Acta 2004, 348, 1-8.
43. Choi, S.H.; Bielory, L. Late-phase reaction in ocular allergy. Curr. Opin. Allergy Clin. Immunol. 2008, 8, 438-444.
44. Sezer, E.D.; Sozmen, E.Y.; Nart, D.; Onat, T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc. Health Risk Manag. 2011, 7, 333-343.
45. Wassmann, S.; Czech, T.; van Eickels, M.; Fleming, I.; Bohm, M.; Nickenig, G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein e/angiotensin ii type 1a receptor double-knockout mice. Circulation 2004, 110, 3062-3067.
46. Peng, N.; Meng, N.; Wang, S.; Zhao, F.; Zhao, J.; Su, L.; Zhang, S.; Zhang, Y.; Zhao, B.; Miao, J. An activator of mtor inhibits oxldl-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein e(-)/(-) mice. Sci. Rep. 2014, 4, 5519.
47. Yoshioka, K.; Yoshida, K.; Cui, H.; Wakayama, T.; Takuwa, N.; Okamoto, Y.; Du, W.; Qi, X.; Asanuma, K.; Sugihara, K.; et al. Endothelial pi3k-c2alpha, a class ii pi3k, has an essential role in angiogenesis and vascular barrier function. Nat. Med. 2012, 18, 1560-1569.
48. Ramkhelawon, B.; Vilar, J.; Rivas, D.; Mees, B.; de Crom, R.; Tedgui, A.; Lehoux, S. Shear stress regulates angiotensin type 1 receptor expression in endothelial cells. Circ. Res. 2009, 105, 869-875.
49. Kawashima, S. The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium 2004, 11, 99-107.
50. Simoncini, T.; Genazzani, A.R. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J. Clin. Endocrinol. Metab. 2000, 85, 2966-2969.
51. Domagala, T.B.; Szeffler, A.; Dobrucki, L.W.; Dropinski, J.; Polanski, S.; Leszczynska-Wiloch, M.; Kotula-Horowitz, K.; Wojciechowski, J.; Wojnowski, L.; Szczeklik, A.; et al. Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by n1-methylnicotinamide in human blood vessels. Hypertension 2012, 59, 825-832.
52. Musicki, B.; Kramer, M.F.; Becker, R.E.; Burnett, A.L. Inactivation of phosphorylated endothelial nitric oxide synthase (ser-1177) by o-glcnac in diabetes-associated erectile dysfunction. Proc. Natl. Acad. Sci. USA 2005, 102, 11870-11875.
53. Fleming, I.; Fisslthaler, B.; Dimmeler, S.; Kemp, B.E.; Busse, R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ. Res. 2001, 88, E68-E75.
54. Fleming, I.; Busse, R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284, R1-R12.